SCHEMBL7517543

SCHEMBL7517543

Cn1c(-c2ccc(C=O)cc2)nc2cc(Cl)c(Cl)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS12 P56730 4/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HDAC1 Q13547 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC3 O15379 1/20 0.40
HDAC2 Q92769 1/20 0.40
BRD4 O60885 1/20 0.40
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
PKM P14618 3/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7519324 0.81 KDM4E (0.52) MEN1KMT2ABRD4KDM4EALDH1A1
SCHEMBL31474770 0.81 KDM4E (0.60) PRSS12PTGDR2CA1CA2CA12
SCHEMBL7513237 0.80 BRD4 (0.43) MEN1KMT2AHDAC1HDAC8HDAC6
SCHEMBL17896659 0.79 MEN1 (0.59) PRSS12PTGDR2CA1CA2CA12
SCHEMBL19763372 0.78 CA1 (0.51) CA1CA2CA12CA9MEN1
SCHEMBL19763374 0.78 KDM4E (0.48) CA1CA2CA12CA9MEN1
SCHEMBL7520977 0.78 MGAM (0.53) RAB9ANPC1GAAHPGDHTT
SCHEMBL7520980 0.78 MGAM (0.53) RAB9ANPC1GAAHPGDHTT
SCHEMBL31474742 0.78 ALDH1A1 (0.65) PRSS12PTGDR2CA1CA2CA12
SCHEMBL28569089 0.78 ALDH1A1 (0.65) PTGDR2CA1CA2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 PRSS12 2834/4885PTGDR2 3157/4885CA1 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.